Adaptive Biotechnologies (ADPT) CPO sells 39,741 shares after option exercises
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock. On June 4, 2026, Lo exercised options covering 19,521 shares at strike prices ranging from $3.99 to $12.14 per share, receiving an equivalent number of common shares.
On the same date, Lo completed an open-market sale of 39,741 Common Stock shares at an average price of $17.49 per share. Following these transactions, Lo holds 250,934 Common Stock shares directly and 2,500 shares indirectly through a spouse. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 5,792 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 2,009 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 2,344 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 9,376 | $0.00 | -- |
| Exercise | Common Stock | 5,792 | $12.14 | $70K |
| Exercise | Common Stock | 2,009 | $8.46 | $17K |
| Exercise | Common Stock | 2,344 | $3.99 | $9K |
| Exercise | Common Stock | 9,376 | $8.12 | $76K |
| Sale | Common Stock | 39,741 | $17.49 | $695K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The option is fully vested and exercisable. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.